John Nowins, MD
Obstetrics & Gynecology · Las Vegas, NVNPI 1912047176
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Novo Nordisk accounts for 67.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $243 and has fallen 87.1% since, to $31 in 2025. That places this record below the midpoint for obstetrics & gynecology clinicians in NV, where the typical reported total is $836.
Across 66 payments — averaging $12.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$566
- AbbVie$53
- Myovant Sciences Inc.$44
- Phathom Pharmaceuticals, Inc.$34
- Teva Pharmaceuticals USA, Inc.$32
- Amgen$31
- plus $77 from 5 others
What the payments were for
- Food & beverage$80496%
- Education$324%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 49 | $566 |
| AbbVie | 3 | $53 |
| Myovant Sciences Inc. | 3 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Amgen | 1 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Organon | 1 | $13 |
| Lupin Inc. | 1 | $12 |
| Therapeuticsmd, Inc. | 1 | $11 |
How this compares
$836 in reported general payments places this provider in the 50th percentile of 308 obstetrics & gynecology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 11 | $11,477 |
| EliquisApixaban | 11 | $5,940 |
| MovantikNaloxegol Oxalate | 13 | $5,100 |
| Alprazolam | 43 | $163 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $152 |
| Allopurinol | 23 | $144 |
| Levothyroxine Sodium | 15 | $104 |
| Lisinopril | 14 | $100 |
| Atorvastatin Calcium | 19 | $90 |
| Oxycodone Hcl | 12 | $88 |
| Omeprazole | 20 | $59 |
| Montelukast Sodium | 22 | $58 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Las Vegas
- Darin SwainstonLas Vegas$713K
- Christina KushnirLas Vegas$502K
- Lamarr TylerLas Vegas$170K
- Ralph VennartLas Vegas$144K
- Kenneth VolkerLas Vegas$126K
- Navkaran SinghLas Vegas$104K
- Sunwook KimLas Vegas$94K
- Luis Lopez BenitezLas Vegas$89K
- Linda TranLas Vegas$72K
- Raul Romero JosephLas Vegas$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.